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TO THE EDITOR
The protein kinase BRAF regulates cell
growth through the mitogen-activated
protein kinase (MAPK) pathway. In
about half of the melanomas, BRAF is
mutated and acts as a driver oncogene
that stimulates cell proliferation, survi-
val, and tumor progression (Davies
et al., 2002; Gray-Schopfer et al.,
2007). The anti-BRAF drugs vemurafe-
nib (PLX4032/RG7204) and dabrafenib
(GSK2118436) achieve objective clin-
ical responses in about 60% of mela-
noma patients whose tumors express
mutant BRAF (Flaherty et al., 2010;
Chapman et al., 2011; Sosman et al.,
2012), validating these drugs as a
therapeutic option for BRAF-mutant
melanoma patients.
An unexpected side effect of vemur-
afenib is that it induces keratoacantho-
mas (KA) and well-differentiated
cutaneous squamous cell carcinomas
(cuSCCs) inB26% of patients (Flaherty
et al., 2010; Sosman et al., 2012). This
is because, although BRAF inhibitors
block MAPK signaling in cells harbor-
ing BRAF mutations, they activate the
pathway in cells expressing mutant RAS
(Rat sarcoma) or when RAS is activated
by receptor tyrosine kinases (Hatzivas-
siliou et al., 2010; Heidorn et al., 2010;
Poulikakos et al., 2010). Critically,
21–57% of the nonmelanoma skin
lesions that develop in vemurafenib-
treated patients carry somatic mutations
in HRAS or KRAS (Oberholzer et al.,
2011; Su et al., 2012).
We recently used a mouse two-stage
skin carcinogenesis model to investi-
gate how BRAF inhibitors drive the
development of these nonmelanoma
skin lesions (Su et al., 2012). FVB/N
mice were treated with a single
topical application of the carcinogen 7,
12-dimethylbenz-(a)anthracene (DMBA),
which induces HRAS Q61L mutations
in keratinocytes. The mice were then
treated weekly with the tumor promoter
12-O-tetradecanoyl-phorbol-13-acetate
(TPA) and daily with oral doses of
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Figure 1. 5-Fluorouracil (5-FU) induces regression of the highly proliferative PLX4072-induced lesions in mice. (a) Photomicrographs showing hematoxylin
and eosin (H&E) staining and high proliferation index in a Ki-67 immunohistochemical staining for a papilloma from a 7,12-dimethylbenz-(a)anthracene
(DMBA)-, 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-, and PLX4720-treated animal. Proliferation is more pronounced in the lower two-thirds of the
epidermis. (b) Dose–response curves comparing RAS-transformed keratinocytes treated with 5-FU in the presence or absence of PLX4720. (c) Tumor
development in DMBA-, TPA-, and PLX4720-treated mice (DMBA/TPA/PLX). Mice were treated with 5-FU on day 55 (indicated by the gray arrow) applied
topically directly to single lesions twice a week. (d) Photographs show a single mouse from the 5-FU-treated cohort at days 55, 64, and 78. Bar¼ 0.5mm left and
center, 200 mm right.
Abbreviations: CuSCCs, cutaneous squamous cell carcinomas; DMBA, 7,12-dimethylbenz-
(a)anthracene; KA, keratoacanthomas; MAPK, mitogen-activated protein kinase; TPA,
12-O-tetradecanoyl-phorbol-13-acetate; 5-FU, 5-fluorouracil
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PLX4270 (see Supplementary Experi-
mental Procedures online), a BRAF
inhibitor that is preferred for mouse
studies because of its superior oral
bioavailability (Su et al., 2012). We
demonstrated that PLX4720 accelerated
the growth of squamoproliferative le-
sions in DMBA/TPA-treated mice but
did not induce lesions in mice treated
with DMBA alone (Su et al., 2012).
These data demonstrated that vermur-
afenib is not a tumor promoter per se;
rather, it acts by accelerating the
progression of preexisting, premalig-
nant lesions in susceptible individuals.
It is not known whether the cuSCCs
that develop in vemurafenib-treated
patients have metastatic potential dif-
ferent from cuSCCs that develop in the
absence of BRAF inhibition, because
in both the clinical settings these
lesions are treated by surgical excision.
However, advanced-stage melanoma
patients on BRAF inhibitors can devel-
op multiple eruptive lesions early dur-
ing the course of BRAF inhibitor
therapy and these can be challenging
to manage surgically. We therefore
sought to develop a noninvasive ap-
proach to treat these particular patients.
Previous studies have shown that
BRAF inhibitors accelerate the proli-
feration of RAS-transformed cells
(Hatzivassiliou et al., 2010; Heidorn
et al., 2010; Poulikakos et al., 2010;
Su et al., 2012). We confirmed that the
nonmelanoma skin lesions in DMBA/
TPA/PLX4720-treated mice have a high
proliferative index by showing that
they have a high mitotic index (510
high-power fields) and strong positive
staining for Ki-67 (Figure 1a), and
thus we investigated whether anti-
proliferative drugs could induce their
regression.
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Figure 2. 5-Fluorouracil (5-FU) induces regression of BRAF inhibitor–induced squamoproliferative lesions in patients. (a) Eruptive actinic keratosis and nascent
cutaneous squamous cell carcinomas (cuSCCs) on day 9 of dabrafenib therapy in patient #1. Black arrows point at cuSCCs, white arrow points at clinically
diagnosed keratoacanthoma. (b) In patient #1, lesions consistent with a clinical diagnosis of cuSCC were either treated with 5-FU twice daily (equivalent sites
numbered in red and blue arrows) or left untreated (numbered in black) for 28 days, beginning from day 12 of dabrafenib therapy. Lesion marked #1 is a
presumptive seborrheic keratosis, serving as a positional and size reference. (c) In patient #2, who was also treated with dabrafenib against melanoma, two
keratotic cuSCCs were treated simultaneously with twice daily 5-FU applications. Photographs were taken on days 0, 17, 34, and 62 of treatment.
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5-Fluorouracil (5-FU) is an antimeta-
bolite that blocks DNA synthesis and
inhibits cell proliferation. Although topi-
cal application of 5-FU should be
restricted to an area no greater than
500cm2 (approximately the area of an
extended hand) (MedaPharmaceuticals,
2012), 5-FU is inexpensive and achieves
objective clinical responses in 46–87%
of cases of solar keratosis, lesions that are
the precursor of invasive cuSCC (Gray
and Meland, 2000; Shimizu et al., 2011).
We confirm that 5-FU inhibited the
growth of PDV cells, an HRAS mutant
keratinocyte line, with IC50 (half max-
imal inhibitory concentration 50) values
of B4.43mM in the absence of PLX4720
and B1.67mM in its presence (Figure
1b). To test 5-FU in vivo, FVB/N mice
(six animals per group) were treated with
DMBA, TPA, and PLX4720 as described
(Su et al., 2012). As reported (Su et al.,
2012), palpable lesions first appeared
after 30 days, increasing in number to
approximately 11 lesions per mouse in
55 days (Figure 1c). We then treated the
individual lesions with topical 5% 5-FU
cream twice a week. Left untreated, we
have shown that the tumors continue to
grow and reach tumor burden limits after
approximately 90 days (Su et al., 2012);
however, with 5-FU, we observed an
immediate response, with tumor regres-
sion leading to complete remission with-
in 25 days (Figure 1c and d).
On the basis of these observations,
we tested the efficacy of 5-FU in two
melanoma patients who were being
treated with the BRAF inhibitor dabra-
fenib (GSK2118436). Both patients ra-
pidly developed multiple eruptive
lesions consistent with actinic keratosis
and/or cuSCC (Figure 2a and b). In-
dividual lesions were treated with 5%
5-FU cream twice a day, respecting
recommended safety guidelines for total
skin treatment area. Photo-documented
lesions presenting the characteristics of
KA and cuSCCs at various stages re-
sponded to 5-FU, whereas untreated
concurrent lesions progressed and after
biopsy were confirmed to be bona fide
cuSCCs (Figure 2b and c). During
follow-up periods of 11 and 18 months,
respectively, none of the treated lesions
in patients 1 and 2 recurred. As noted in
these anecdotal cases, nascent lesions
tended to respond more quickly com-
pared with the established hyperkerato-
tic lesions.
Secondary malignancies induced by
conventional chemotherapies generally
take many years to develop (Curtis
et al., 1992), but the nonmelanoma
skin lesions induced by BRAF inhibitors
develop within weeks of initiating
treatment (Su et al., 2012). Our pre-
vious studies show that BRAF inhibitors
are not carcinogens per se; rather, they
act to accelerate the development of
preexisting subclinical lesions in sus-
ceptible patients. The approval of ve-
murafenib raises a pressing clinical
need to provide treatment guidelines
to manage these secondary lesions in
patients for whom surgery is an un-
desirable option. The observation that
BRAF inhibitors drive proliferation of
RAS-mutant keratinocytes led us to test
the efficacy of antiproliferative agents.
We show that 5-FU provides a safe,
noninvasive, inexpensive, and effective
alternative to surgical intervention in
clinical cases in which multiple sur-
geries are difficult or in cases in which
lesions are incipient.
Details concerning the ethics of
animal and human studies are provided
in the Supplementary Materials online.
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